Building A FAT Loss Peptide Stack

Why the stacking question matters

Fat loss is not a one-mechanism problem. Your body has multiple parallel systems controlling appetite, glucose handling, lipolysis, mitochondrial energy production, GH pulsatility, and adipocyte biology — and the reason single-compound protocols hit diminishing returns is that they only engage one of those systems while the others sit at baseline (or worse, compensate downward).

The shift in framing that changes outcomes: stop thinking “which peptide is the strongest fat-burner?” and start thinking “which combination of mechanisms keeps every fat-loss pathway working at once?”

The four mechanism layers worth pulling together:

Layer	What it does	Lead compounds
GLP-class systemic	Appetite suppression + delayed gastric emptying + insulin sensitivity + (with glucagon arm) liver-driven fat mobilization and thermogenesis	Retatrutide, Tirzepatide, Semaglutide
Mitochondrial biogenesis	Activates AMPK; signals cells to burn fat for fuel; exercise-mimetic without CNS stimulation	MOTS-c
Mitochondrial protection	Repairs the inner mitochondrial membrane (where ATP is produced); restores cellular energy output; reduces oxidative stress	SS-31 (Elamipretide)
GH-axis optimization	Endogenous growth hormone release for fat oxidation + lean-tissue preservation; with Tesamorelin, specifically targets visceral fat	Tesamorelin, CJC-1295 / Ipamorelin

The stack works because the mechanisms complement each other — the GLP-class drives systemic fat-loss demand, the mitochondrial pair makes sure your cellular machinery can handle the demand, and the GH-axis layer preserves lean tissue against the muscle-loss tail that’s class-wide across the GLP RAs. None of these is the right tool alone for the outcome you actually want.

The four-layer framework, layer by layer

Layer 1 — The GLP-class systemic anchor

This is the compound that drives the systemic fat-loss signaling — the satiety, the slowed gastric emptying, the appetite control, and (with the dual and triple agonists) the additional insulin-sensitivity and liver-fat-mobilization arms.

The molecules in this class, in order of mechanism breadth:

• Semaglutide — single GLP-1 receptor agonist. The molecule that established the modern GLP-1 obesity paradigm. The deepest published RCT evidence base in the category (STEP-1, STEP-2, etc.). FDA-approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). The right first-line option for many patients — prescriber familiarity, insurance coverage, accessible compounded versions.
• Tirzepatide — dual GLP-1 + GIP agonist. The GIP arm works synergistically with GLP-1 to enhance insulin sensitivity and improve fat oxidation. Clinical data (SURMOUNT-1, SURMOUNT-2) consistently outperforms semaglutide on total weight loss. Better-tolerated side-effect profile for most users — less nausea, fewer GI issues, better adherence.
• Retatrutide — triple agonist (GLP-1 + GIP + glucagon receptors), the flagship of the category. The glucagon arm is the addition that changes the equation — it signals the liver to mobilize stored fat for energy, cranks up thermogenesis, and pushes the body into around-the-clock fat oxidation including at rest. Phase 2 trial data: at the 12 mg/week dose at 48 weeks, participants lost an average of 24.2% of body weight vs 2.1% on placebo (Jastreboff et al., NEJM 2023, PMID 37366315). Nearly two-thirds of the 12 mg cohort lost ≥20% body weight; half lost ≥25%; one-quarter lost >30%.

The class-wide caveat: every GLP-class compound carries a muscle-loss tail when run without supportive structure. The body doesn’t discriminate between fat and lean tissue when total body weight drops under a steep caloric deficit. The lean-tissue protection comes from adequate protein intake (~1 g per pound of target body weight), resistance training, Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1), and the GH-axis Layer 4 below. This is a solvable problem — the molecule isn’t the issue, the protocol around it is.

Which compound is right for which user: the verified-supply Retatrutide pathway (Alyve catalog, Retatrutide for the dosing protocol) is the highest-output option if you have access. If your prescriber is writing Tirzepatide, that’s a solid step up from semaglutide and the right tool. If you only have access to semaglutide, that’s still a legitimate and effective tool — the muscle-loss tail is class-wide, and a semaglutide protocol with proper protein + resistance training + creatine + the mitochondrial and GH-axis layers below outperforms a Reta protocol without supportive structure.

Layer 2 — Mitochondrial biogenesis (MOTS-c)

When you place significant metabolic demand on your cells (which is what Layer 1 does), your mitochondria need to be running at full capacity to capitalize on the signaling. Without that, you’re asking the body to burn fat at scale while the cellular machinery that actually does the burning is sub-optimal.

MOTS-c is a mitochondrial-derived peptide — encoded in your own mitochondrial DNA, produced naturally by your body. Production declines with age, chronic stress, poor sleep, and metabolic dysfunction. The mechanism:

• Activates AMPK — one of the most important metabolic switches in the body. AMPK activation signals cells to start burning fat for fuel instead of storing it.
• Improves insulin sensitivity and enhances glucose uptake in muscle tissue.
• Increases overall metabolic rate without stimulating the central nervous system (no jittery / wired feeling).
• Acts as an exercise mimetic — research shows direct anti-obesity effects in animal models independent of caloric intake. The body gets better at burning fat even when diet isn’t perfect.
• Also improves exercise capacity and endurance — you train harder and recover faster, which compounds the fat-loss effect over time.

Typical dosing: practitioners commonly run MOTS-c at 5-10 mg/week SubQ, sometimes 2-3 administrations of 2-4 mg distributed across the week. Some protocols run lower daily doses (1-2 mg) for sustained signaling.

Layer 3 — Mitochondrial protection (SS-31 (Elamipretide))

Where MOTS-c activates your metabolic machinery, SS-31 (Elamipretide) (Elamipretide) repairs and preserves it. As mitochondria age, the inner membrane (where ATP is actually produced) deteriorates → cells produce less ATP → metabolism slows → fat-burning becomes less efficient → energy drops.

SS-31 directly targets the inner mitochondrial membrane, binds cardiolipin, reduces oxidative stress, and restores mitochondrial function back toward younger-baseline efficiency.

It’s not a dramatic standalone fat-burner — and that’s not the point. The point is that every other compound in the stack works better when mitochondria are healthy and efficient. Stacked with MOTS-c, you have a mitochondrial-optimized cellular environment most fat-loss protocols never address.

SS-31’s secondary value: the cardiovascular protective effect that nothing else in the stack offers. Improves cardiac output, reduces inflammation at the cellular level, shows promising results in research around heart failure and metabolic disease. SS-31 is the first FDA-approved mitochondrial-targeted peptide (Barth syndrome, FORTIFY trial data, 2025 approval) — the regulatory record is the strongest of any compound in the mitochondrial-targeting category.

Typical dosing: practitioners commonly run SS-31 at 5-10 mg/day SubQ. Some protocols run higher initial loading doses and taper to maintenance.

Layer 4 — GH-axis optimization (Tesamorelin + CJC-1295 / Ipamorelin)

Eight weeks into any meaningful caloric deficit, muscle protection becomes as important as continued fat loss. This is where the GH-axis layer earns its place.

Tesamorelin is the specific compound the practitioner-camp consensus rates highest:

• GHRH analog — stimulates the pituitary to produce and release endogenous growth hormone in a physiological pulse pattern. Your own GH, produced the way your body is designed to produce it. Not synthetic HGH injected from the outside.
• The only GH-axis peptide specifically developed and FDA-approved to target visceral fat (HIV-associated lipodystrophy indication; off-label for visceral fat in general). Goes after the deep abdominal fat wrapped around organs — the stubborn fat that diet and exercise alone often can’t move.
• Improves IGF-1 levels and supports lean muscle retention.
• Notably clean side-effect profile relative to other GH-axis peptides.

CJC-1295 / Ipamorelin is the broader GH-axis stack:

• CJC-1295 = GHRH analog (same class as Tesamorelin). Stimulates the pituitary to produce/release GH.
• Ipamorelin = GHRP (growth-hormone-releasing peptide). Works through a separate receptor (ghrelin/GHS-R1a) to trigger GH release AND suppresses somatostatin (the hormone that tells the body to stop producing GH).
• Why stack them: the two compounds together produce a significantly larger and cleaner GH pulse than either alone. Better fat oxidation, better muscle retention, better recovery, better sleep quality.

How to decide which GH-axis layer to use: Tesamorelin is more targeted (visceral fat) and more clinically validated. CJC + Ipa is broader — optimizes overall GH output for systemic muscle preservation rather than targeting a specific fat depot. Some users run both; some pick one. If you’re new to GH-axis peptides, CJC + Ipa is the more accessible entry point. If you want the visceral-fat-specific lever, Tesamorelin is the right tool.

Typical dosing:

• Tesamorelin: 0.5-1 mg SubQ five days/week, pre-bedtime.
• CJC-1295 + Ipamorelin: 200-400 mcg CJC + 100-300 mcg Ipa SubQ taken together pre-bed, 5 days/week.

The 12-week sequenced protocol

Layering all four mechanisms simultaneously from day one is a mistake — you can’t tell which compound is doing what, you can’t titrate cleanly, and the side-effect profile is unmanageable. The practitioner-camp consensus on sequencing:

Week 1 — Anchor with the GLP-class compound

• Start with Retatrutide (or whichever GLP-class compound you have access to) at the lowest titration dose — for Reta, that’s 0.5 mg SubQ once weekly.
• Solo first. No other peptides added at this point. The goal is to establish tolerance and titration before anything else gets layered on.
• Why this comes first: the GLP-class systemic signaling is the strongest driver of fat-loss output, and you need it established at a meaningful dose before the supporting layers add value.

Weeks 2-7 — Continue titrating the GLP-class anchor

• Titrate Retatrutide slowly up to 3-4 mg/week over 6-8 weeks. Half-mg increments every 2-4 weeks based on tolerance.
• This is also the window where you lock in the foundation that supports the entire stack: ~1 g protein/lb target body weight, resistance training 3-4x/week, Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1) 5 g/day, adequate sleep, hydration. The molecule does its job; the foundation lets the body use that job for the outcome you want.
• Don’t sub-therapeutic-dose Retatrutide if your goal is fat loss. The mechanism needs to engage at a meaningful dose to deliver the outcome. Micro-dosing is a separate use case (metabolic-tuning at low load); it doesn’t drive the 20%+ body-weight outcomes the Phase 2 trial documented.

Weeks 2-8 — Add the mitochondrial pair (MOTS-c + SS-31)

• Once Retatrutide is established and tolerating well, add MOTS-c (5-10 mg/week SubQ) AND SS-31 (Elamipretide) (5-10 mg/day SubQ) together.
• Why this layer second: Reta is placing meaningful metabolic demand on your cells. The mitochondrial pair ensures your cellular machinery is running at full capacity to capitalize on the systemic signaling.
• This is the “your body is being asked to do a lot of work — let’s make sure it can” layer.

Weeks 8+ — Add the GH-axis layer

• Add the GH-axis layer when you’re 8+ weeks into the caloric deficit and lean-tissue preservation becomes a primary concern.
• Option A — broader systemic GH optimization: CJC-1295 / Ipamorelin (200-400 mcg CJC + 100-300 mcg Ipa SubQ pre-bed, 5 days/week).
• Option B — visceral-fat-specific: Tesamorelin (0.5-1 mg SubQ five days/week, pre-bedtime).
• Option C — both: advanced protocol. Adds CJC + Ipa for systemic muscle preservation AND Tesamorelin for the visceral-fat depot. Used by experienced stackers running aggressive 90+ day cuts.

Week 12 — Full stack running

• Appetite regulation (Reta) + mitochondrial efficiency (MOTS-c + SS-31) + GH-axis optimization (CJC + Ipa) + visceral-fat targeting (Tesamorelin) all running simultaneously.
• This is the four-mechanism stack the entire framework builds toward. Layered, sequenced, with foundation in place — not piled on from day one.

What about the other compounds — AOD-9604, SLU-PP-332, 5-Amino-1MQ?

These are commonly discussed fat-loss peptides that don’t make the core four-layer stack. The honest read on each:

• AOD-9604 — synthetic fragment of the GH molecule (amino acids 176-191). Stimulates lipolysis, inhibits lipogenesis. Underwhelming as a standalone — the original developer ran completed Phase II obesity trials with negative efficacy results and abandoned the compound. Has a place as a targeted lipolytic supporting compound layered on top of Tesamorelin or CJC + Ipa, NOT as primary therapy. See Metabolic / fat-loss peptides cluster — AOD-9604, HGH Fragment 176-191, Adipotide, AICAR, SLU-PP-332 for the full evidence record.
• SLU-PP-332 — exercise mimetic, ERR (estrogen-related receptor) agonist. The mechanism is sound, early animal-study signals are promising, but robust human trial data doesn’t yet exist. Short half-life means frequent dosing required. Worth watching closely over the next 12-36 months as human data accumulates; not ready to anchor a serious stack on. See Metabolic / fat-loss peptides cluster — AOD-9604, HGH Fragment 176-191, Adipotide, AICAR, SLU-PP-332 (note: SLU-PP-322 and SLU-PP-332 are related compounds in the SLU research-group series).
• 5-Amino-1MQ — small-molecule NNMT inhibitor, orally bioavailable. Targets adipose tissue directly. As a standalone, practitioner observation has been underwhelming for fat loss. Most useful niche: stacking during a transition or exit-phase from a primary peptide like Retatrutide, to help maintain the metabolic environment as the GLP-class compound is tapered. See 5-Amino-1MQ for the full mechanism and dosing.

What about Melanotan II?

Melanotan II is not a fat-loss tool — it’s a safety problem. Yes, MC4R activation is a potent appetite-suppressing signal and the same receptor pathway pharmaceutical companies are targeting for next-generation obesity drugs. But Melanotan II activates multiple melanocortin receptors non-selectively, and the side-effect profile that follows is rough:

• Nausea (especially during loading)
• Facial flushing
• Spontaneous erections
• Darkening of moles (and documented melanoma-adjacent skin-lesion concerns)
• Elevated blood pressure
• Rhabdomyolysis + acute kidney injury reports in users

The fat-loss effects don’t justify the side-effect profile when the four-layer stack above exists. The OHM Melanotan II wiki carries a red safety flag for Melanotan II — both for fat-loss and for general use. The right MC4R-targeting tools are coming from the pharmaceutical pipeline (next-generation obesity drugs targeting MC4R specifically); Melanotan II in 2026 is not the answer for fat loss.

Where to actually source this stack

For OHM customers building the four-layer stack, the verified-supply path runs through Alyve Peptides for the core compounds:

• Retatrutide — Alyve catalog (10 mg / 20 mg vials, third-party Freedom Diagnostics COA at 99.01% / 99.13%).
• MOTS-c — Alyve catalog.
• Tesamorelin — Alyve catalog (99.46% COA purity).
• CJC-1295 / Ipamorelin — Alyve catalog (blend COA at 99.90% — the cleanest in the launch catalog).

Use OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail.

For SS-31 (Elamipretide) (not in Alyve’s current launch catalog), the verified-supply alternatives are AminoClub (optimalhealthmanifesto.com/aminoclub, code OHM for 20% off) or BioLongevity Labs (optimalhealthmanifesto.com/biolongevity, code OHM-15 for 15% off).

For the GLP-class compounds when sourced through the compounding-pharmacy pathway instead of research-chem, see The compounding pharmacy pathway — 503A, 503B, and why your doctor probably can’t prescribe BPC-157 yet for the regulatory framework and how to think about that supply route honestly.

Cross-references

• Retatrutide · Tirzepatide · Semaglutide · The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide — the GLP-class anchor layer.
• MOTS-c · SS-31 (Elamipretide) — the mitochondrial pair (biogenesis + protection).
• Tesamorelin · CJC-1295 / Ipamorelin · Ipamorelin · CJC-1295 — the GH-axis layer.
• Metabolic / fat-loss peptides cluster — AOD-9604, HGH Fragment 176-191, Adipotide, AICAR, SLU-PP-332 — AOD-9604, SLU-PP-322 (related to SLU-PP-332), 5-Amino-1MQ, and the broader fat-loss-cluster context.
• 5-Amino-1MQ · Melanotan II — the surrounding compounds discussed honestly above.
• Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1) — the foundational adjunct for muscle preservation on any GLP-class protocol.
• The compounding pharmacy pathway — 503A, 503B, and why your doctor probably can’t prescribe BPC-157 yet — the 503A/503B pathway context for GLP-class compounds sourced through compounding pharmacies.
• How to read a peptide Certificate of Analysis (and spot a fake) · The major peptide third-party testing labs — who they are, what they actually do, and which one to use when — the verification framework for any peptide you actually source.

---

Last updated: 2026-06-21. Created from — Nicholas Trigili 12-peptide fat-loss tier-ranking + 12-week stack synthesis. The Retatrutide Phase 2 24.2% body-weight reduction at 48 weeks is anchored to the verified Jastreboff et al. 2023 NEJM primary source (PMID 37366315). All other mechanism / dosing / safety claims cross-reference the existing per-peptide OHM wiki articles. Source-video tier-list framing reframed in OHM voice — the engagement-bait “F-tier semaglutide” dismissal is rewritten as “foundational tool with the deepest evidence base; the muscle-loss tail is class-wide, not unique.” The Melanotan-II safety flag is preserved per the existing Melanotan II wiki. All practitioner content paraphrased into OHM voice per Doctrine #3 — zero verbatim quotes from the source video.